PHILADELPHIA, PA (June 6, 2017) — In its third consecutive year in the top ten, the global provider of medical and healthcare services maintains its 2016 position. M3 Inc. is the parent company of US-based organizations MDLinx and M3 Global Research, a leader in healthcare market research who provide comprehensive and unrivalled recruitment and support services to the industry.
Anton Richter, CEO of M3 Global Research said today: “We are honored to maintain our position on the Forbes ‘Most Innovative Growth Companies’ list. It reflects our investment in the expansion of our services and extending our global reach, and we are constantly adding amazing talent to our team, as well as working closely with our colleagues globally to collaborate, integrate, and develop innovative offerings to our HCP members, as well as unique programs and services for our clients.”
The Forbes ‘Most Innovative Growth Companies’ list is compiled using several metrics and factors, including ‘investors' ability to identify firms they expect to be innovative now and in the future.’ Companies on the list are ranked by what the creators, Hal Gregersen and Jeff Dyer refer to as the ‘innovation premium,’ which they define as ‘the difference between their market capitalization and the net present value of cash flows from existing businesses.’ This list includes mid-cap companies with a market value of $2-10 billion.
‘Innovation is integral at all levels of our organization, and contributes significantly to our success in market research recruitment across the globe. We are extremely fortunate to have such a depth of resources and an innate commitment to continuous improvement, which strengthens the bottom line for our market research deliverables.” added Richter.
About M3 Group
The M3 Group operates in the US, Asia, and Europe with over 5.8 million physician members globally via its physician websites which include mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net, medlive.cn, and m3india.in. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, France, Japan, China, and India. The M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Japan, UK, France, Germany, Spain, USA, Sweden, China, South Korea, and India.